Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Elite controllers may pay a high price for their low viral load

About one in 200 people with HIV maintains an undetectable viral load and high CD4 counts without having to take antiretroviral therapy (ART). These so-called ‘elite controllers’

Published
07 January 2015
By
Gus Cairns
US guidelines on prevention with people living with HIV now emphasise engagement with care, HIV treatment and social factors

The American public health agency, the Centers for Disease Control and Prevention (CDC) has published new recommendations on the HIV prevention interventions and advice that should

Published
05 January 2015
By
Roger Pebody
HIV vaccines should avoid viral target cells, primate model study suggests

Vaccines designed to protect against HIV can backfire and lead to increased rates of infection. This unfortunate effect has been seen in more than one vaccine clinical trial. Scientists at Yerkes National Primate Research Center, Emory University, have newly published results that support a straightforward explanation for the backfire effect: vaccination may increase the number of immune cells that serve as viral targets.

Published
04 January 2015
From
EurekAlert
Gilead, Janssen Expand HIV Combo Collaborations

Janssen R&D Ireland and Gilead Sciences have expanded two existing HIV drug collaborations through agreements to develop new once-daily HIV tablets, the companies said today in separate announcements. The value of both collaborations was not disclosed.

Published
30 December 2014
From
Genetic Engineering & Biotechnology News
Gilead Sciences, Inc. Can't Do It Alone

On Monday, Gilead Sciences announced an expanded agreement with Johnson & Johnson to develop two different of cocktail pills to treat HIV. One drug will combine Gilead's tenofovir alafenamide, commonly called TAF, and Emtriva with Johnson & Johnson's Edurant. The other combines Gilead's TAF, Emtriva, and Tybost, along with Janssen's Prezista.

Published
30 December 2014
From
Motley Fool
New open-access journal in the rapidly developing field of virus eradication

The Journal of Virus Eradication is a new open-access online and print journal dedicated to the rapidly developing field of virus eradication. It is particularly interested in publishing original research on HIV, hepatitis viruses, HPV, herpes and flu but work on other viruses is also included. The first issue was successfully launched at the HIV and Hepatitis Five Nations Conference in London on 8 December 2014 and is available now on the Journal website: www.viruseradication.com

Published
23 December 2014
From
Mediscript
A Fresh Setback for Efforts to Cure HIV Infection

Researchers are reporting another disappointment for efforts to cure infection with the AIDS virus. Six patients given blood-cell transplants similar to one that cured a man known as "the Berlin patient" have failed, and all six patients died.

Published
18 December 2014
From
ABC News
Can AIDS be cured?

The fight against AIDS is following a trajectory similar to that of the fight against many cancers. When I was growing up, in the nineteen-fifties, childhood leukemia was nearly always fatal. Eventually, drugs were developed that drove the cancer into remission for months or years, but it always came back.

Published
17 December 2014
From
The New Yorker
Smoking doubles risk of death for patients taking HIV therapy

Smoking doubles the mortality risk for people with HIV taking antiretroviral therapy, a study published in AIDS shows. Smokers had an increased risk of death from cardiovascular disease

Published
16 December 2014
By
Michael Carter
Drug-resistant infections could lead to 10 million extra deaths a year – report

The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.

Published
11 December 2014
From
The Guardian

Filter by country